{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:23:19Z","timestamp":1792664599078,"version":"4.5.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ctrv.2014.11.003","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T07:01:01Z","timestamp":1416812461000},"page":"170-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Emerging therapeutic targets in bladder cancer"],"prefix":"10.1016","volume":"41","author":[{"given":"Benedito A.","family":"Carneiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Meeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Kuzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Scaranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarki A.","family":"Abdulkadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2014.11.003_b0005","unstructured":"Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from: http:\/\/globocan.iarc.fr; 2013 [accessed 2013]."},{"issue":"1","key":"10.1016\/j.ctrv.2014.11.003_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ctrv.2014.11.003_b0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0020","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ctrv.2014.11.003_b0025","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ctrv.2014.11.003_b0030","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.11.003_b0035","doi-asserted-by":"crossref","unstructured":"Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507(7492):315\u201322.","DOI":"10.1038\/nature12965"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.ctrv.2014.11.003_b0045","doi-asserted-by":"crossref","unstructured":"Raju R, Palapetta SM, Sandhya VK, Sahu A, Alipoor A, Balakrishnan L. A network map of FGF-1\/FGFR signaling system. 2014;2014:962962.","DOI":"10.1155\/2014\/962962"},{"key":"10.1016\/j.ctrv.2014.11.003_b0050","first-page":"45","article-title":"Signaling, internalization, and intracellular activity of fibroblast growth factor","volume":"286","author":"Pandey","year":"2004","journal-title":"J Signal Transduct"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0055","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H","article-title":"An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release","volume":"92","author":"Aigner","year":"2001","journal-title":"Int J Cancer J Int Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2014.11.003_b0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)80919-8","article-title":"Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways","volume":"92","author":"Hacohen","year":"1998","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ctrv.2014.11.003_b0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0378-1119(01)00518-2","article-title":"Identification of a new fibroblast growth factor receptor, FGFR5","volume":"271","author":"Sleeman","year":"2001","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0070","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ng1194-269","article-title":"A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome","volume":"8","author":"Muenke","year":"1994","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0075","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/ng1122","article-title":"Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome","volume":"33","author":"Dode","year":"2003","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.ctrv.2014.11.003_b0080","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ng0696-233","article-title":"Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia","volume":"13","author":"Naski","year":"1996","journal-title":"Nat Genet"},{"issue":"40","key":"10.1016\/j.ctrv.2014.11.003_b0085","doi-asserted-by":"crossref","first-page":"14344","DOI":"10.1073\/pnas.0507200102","article-title":"Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas","volume":"102","author":"Rand","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.ctrv.2014.11.003_b0090","first-page":"1063","article-title":"Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer","volume":"5","author":"Giri","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0095","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ajhg.2008.02.008","article-title":"Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"82","author":"Antoniou","year":"2008","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0100","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.ctrv.2014.11.003_b0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ijc.20204","article-title":"Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma","volume":"111","author":"Streit","year":"2004","journal-title":"Int J Cancer J Int Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2014.11.003_b0110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/12615","article-title":"Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas","volume":"23","author":"Cappellen","year":"1999","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.ctrv.2014.11.003_b0115","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/sj.onc.1204110","article-title":"Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma","volume":"20","author":"Sibley","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2014.11.003_b0120","doi-asserted-by":"crossref","first-page":"429213","DOI":"10.1155\/2012\/429213","article-title":"A decade of FGF receptor research in bladder cancer: past, present, and future challenges","volume":"2012","author":"di Martino","year":"2012","journal-title":"Adv Urol"},{"issue":"5s","key":"10.1016\/j.ctrv.2014.11.003_b0125","article-title":"The FGFR landscape in cancer: an analysis of 4,869 cases","volume":"32","author":"Helsten","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.11.003_b0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0135","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.ctrv.2014.11.003_b0140","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-11-0306","article-title":"A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"25","key":"10.1016\/j.ctrv.2014.11.003_b0145","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/onc.2012.319","article-title":"Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance","volume":"32","author":"Chell","year":"2013","journal-title":"Oncogene"},{"issue":"5s","key":"10.1016\/j.ctrv.2014.11.003_b0150","article-title":"Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors","volume":"32","author":"Bahleda","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2014.11.003_b0155","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/jcp.24083","article-title":"Role of FGFs\/FGFRs in skeletal development and bone regeneration","volume":"227","author":"Du","year":"2012","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ctrv.2014.11.003_b0160","doi-asserted-by":"crossref","unstructured":"Sequist LV, Cassier P, Varga A, Tabernero J, Schellens JHM, Delord J, et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. In: Proceedings of the 105th annual meeting of the American Association for Cancer Research; 2014 Apr 5\u20139; San Diego Philadelphia (PA): AACR; 2014 [Abstract nr CT326].","DOI":"10.1158\/1538-7445.AM2014-CT326"},{"key":"10.1016\/j.ctrv.2014.11.003_b0165","doi-asserted-by":"crossref","unstructured":"Tie J, Bang Y, Park YS, Kang Y, Monteith D, Hartsock K, et al. A phase I trial of LY2874455, a fibroblast growth factor receptor inhibitor, in patients with advanced cancer. In: Proceedings of the 105th annual meeting of the American Association for Cancer Research; 2014 Apr 5\u20139; San Diego Philadelphia (PA): AACR; 2014 [Abstract nr CT215 2014].","DOI":"10.1158\/1538-7445.AM2014-CT215"},{"issue":"Suppl. 6","key":"10.1016\/j.ctrv.2014.11.003_b0170","article-title":"Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3","volume":"31","author":"Milowsky","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2014.11.003_b0175","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","article-title":"Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer","volume":"15","author":"Platt","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2014.11.003_b0180","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/onc.2009.315","article-title":"AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K","volume":"29","author":"Askham","year":"2010","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0185","doi-asserted-by":"crossref","first-page":"e18583","DOI":"10.1371\/journal.pone.0018583","article-title":"A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1","volume":"6","author":"Sjodahl","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2014.11.003_b0190","article-title":"Targeting the genetic alterations of the PI3K\u2013AKT\u2013mTOR pathway: its potential use in the treatment of bladder cancers","author":"Houede","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0195","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s10637-014-0082-9","article-title":"Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"32","author":"Rodon","year":"2014","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0200","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000322986","article-title":"Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells","volume":"86","author":"Wu","year":"2011","journal-title":"Urol Int"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0205","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0210","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3892\/ijo.2014.2505","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells","volume":"45","author":"Moon du","year":"2014","journal-title":"Int J Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0215","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00280-014-2376-1","article-title":"Patient-derived xenografts reveal limits to PI3K\/mTOR- and MEK-mediated inhibition of bladder cancer","volume":"73","author":"Cirone","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5s","key":"10.1016\/j.ctrv.2014.11.003_b0220","article-title":"A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors","volume":"32","author":"Juric","year":"2014","journal-title":"J Clinical Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2014.11.003_b0225","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0959-8049(02)00127-2","article-title":"Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours","volume":"38","author":"Crul","year":"2002","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2014.11.003_b0230","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1517\/13543784.2013.826648","article-title":"Perifosine \u2013 a new option in treatment of acute myeloid leukemia?","volume":"22","author":"Krawczyk","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0235","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","article-title":"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background","volume":"11","author":"Davies","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0240","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1464-410X.2012.11720.x","article-title":"Phase II study of everolimus in metastatic urothelial cancer","volume":"112","author":"Milowsky","year":"2013","journal-title":"BJU Int"},{"issue":"6104","key":"10.1016\/j.ctrv.2014.11.003_b0245","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ctrv.2014.11.003_b0250","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1093\/annonc\/mds057","article-title":"Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers","volume":"23","author":"Seront","year":"2012","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0255","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1007\/s12032-012-0216-x","article-title":"A phase II trial of temsirolimus in second-line metastatic urothelial cancer","volume":"29","author":"Gerullis","year":"2012","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0260","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.urolonc.2013.06.002","article-title":"The combination of an mTORc1\/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro","volume":"32","author":"Becker","year":"2014","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2014.11.003_b0265","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ctrv.2014.11.003_b0270","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discovery"},{"issue":"1","key":"10.1016\/j.ctrv.2014.11.003_b0275","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.11.003_b0280","doi-asserted-by":"crossref","first-page":"181964","DOI":"10.1155\/2012\/181964","article-title":"Clinical significance of ErbB receptor family in urothelial carcinoma of the bladder: a systematic review and meta-analysis","volume":"2012","author":"Tsai","year":"2012","journal-title":"Adv Urol"},{"key":"10.1016\/j.ctrv.2014.11.003_b0285","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.e15515","article-title":"Prognostic value of HER2 expression in patients with bladder cancer treated with radical cystectomy: a biomarker study","volume":"32","author":"Erben","year":"2014","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2014.11.003_b0290","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2014.11.003_b0295","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.24337","article-title":"A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma","volume":"115","author":"Wulfing","year":"2009","journal-title":"Cancer"},{"issue":"4s","key":"10.1016\/j.ctrv.2014.11.003_b0300","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.juro.2014.02.663","article-title":"Targeting HER2 with trastuzumab-DM1 (T-DM1) in HER2-overexpressing bladder cancer","volume":"191","author":"Hayashi","year":"2014","journal-title":"J Urol"},{"issue":"5s","key":"10.1016\/j.ctrv.2014.11.003_b0305","article-title":"A phase 1 study of MM-111, a bispecific HER2\/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors","volume":"32","author":"Richards","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5s","key":"10.1016\/j.ctrv.2014.11.003_b0310","article-title":"Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence","volume":"32","author":"Bajorin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2014.11.003_b0315","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/2496","article-title":"Tumour amplified kinase STK15\/BTAK induces centrosome amplification, aneuploidy and transformation","volume":"20","author":"Zhou","year":"1998","journal-title":"Nat Genet"},{"issue":"13","key":"10.1016\/j.ctrv.2014.11.003_b0320","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/jnci\/91.13.1160","article-title":"Mitotic kinase expression and colorectal cancer progression","volume":"91","author":"Katayama","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.ctrv.2014.11.003_b0325","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1093\/emboj\/17.11.3052","article-title":"A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers","volume":"17","author":"Bischoff","year":"1998","journal-title":"EMBO J"},{"issue":"18","key":"10.1016\/j.ctrv.2014.11.003_b0330","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/sj.onc.1201065","article-title":"A putative serine\/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines","volume":"14","author":"Sen","year":"1997","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ctrv.2014.11.003_b0335","first-page":"1275","article-title":"The putative serine\/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas","volume":"10","author":"Reichardt","year":"2003","journal-title":"Oncol Rep"},{"issue":"11","key":"10.1016\/j.ctrv.2014.11.003_b0340","first-page":"1371","article-title":"Expression of mitotic kinases phospho-aurora A and aurora B correlates with clinical and pathological parameters in bladder neoplasms","volume":"25","author":"Bufo","year":"2010","journal-title":"Histol Histopathol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0345","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.urology.2007.12.026","article-title":"Gene expression study of Aurora-A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer","volume":"72","author":"Comperat","year":"2008","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ctrv.2014.11.003_b0350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/leu.2012.186","article-title":"MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ctrv.2014.11.003_b0355","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1158\/1078-0432.CCR-12-2383","article-title":"The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo","volume":"19","author":"Zhou","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0360","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00280-010-1377-y","article-title":"Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors","volume":"67","author":"Dees","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.ctrv.2014.11.003_b0365","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1158\/1535-7163.MCT-10-0299","article-title":"Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics","volume":"9","author":"Macarulla","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0370","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/pros.20050","article-title":"Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades","volume":"60","author":"Weichert","year":"2004","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.ctrv.2014.11.003_b0375","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.onc.1208272","article-title":"Polo-like kinases (Plks) and cancer","volume":"24","author":"Takai","year":"2005","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0380","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1172\/JCI23043","article-title":"Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer","volume":"115","author":"Nogawa","year":"2005","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0385","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000094416","article-title":"Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer","volume":"70","author":"Yamamoto","year":"2006","journal-title":"Oncology"},{"issue":"18","key":"10.1016\/j.ctrv.2014.11.003_b0390","doi-asserted-by":"crossref","first-page":"15552","DOI":"10.1074\/jbc.M111476200","article-title":"The cyclin-ubiquitin ligase activity of cyclosome\/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk","volume":"277","author":"Golan","year":"2002","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0395","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1097-2765(02)00473-2","article-title":"The dissociation of cohesin from chromosomes in prophase is regulated by polo-like kinase","volume":"9","author":"Sumara","year":"2002","journal-title":"Mol Cell"},{"issue":"9","key":"10.1016\/j.ctrv.2014.11.003_b0400","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","article-title":"BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity","volume":"15","author":"Rudolph","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2014.11.003_b0405","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2011.11.001","article-title":"A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours","volume":"48","author":"Schoffski","year":"2012","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2014.11.003_b0410","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1038\/bjc.2014.195","article-title":"A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies","volume":"110","author":"Lin","year":"2014","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2014.11.003_b0415","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/cncr.28519","article-title":"An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer","volume":"120","author":"Stadler","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.11.003_b0420","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.3018","article-title":"Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors","volume":"30","author":"Dumez","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.11.003_b0425","doi-asserted-by":"crossref","unstructured":"Wu C, Sim H, Ambudkar SV. Human ABCB1 and ABCG2 confer acquired resistance to Polo-like kinase 1 inhibitors, BI 2536, volasertib and GSK641364. In: Proceedings of the 105th annual meeting of the American Association for Cancer Research; 2014 Apr 5\u20139; San Diego Philadelphia (PA): AACR; 2014 [Abstract nr 766 2014].","DOI":"10.1158\/1538-7445.AM2014-766"},{"issue":"11","key":"10.1016\/j.ctrv.2014.11.003_b0430","doi-asserted-by":"crossref","first-page":"e50690","DOI":"10.1371\/journal.pone.0050690","article-title":"Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling","volume":"7","author":"Hepburn","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2014.11.003_b0435","doi-asserted-by":"crossref","unstructured":"Ramanathan RK, Hamburg SI, Borad MJ, Seetharam M, Kundranda MN, Lee P, et al. A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors. In: Proceedings of the 104th annual meeting of the American Association for Cancer Research; 2013 Apr 6\u201310; Washington, DC, Philadelphia (PA): AACR; 2013 [Abstract nr LB-289].","DOI":"10.1158\/1538-7445.AM2013-LB-289"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0440","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/1535-7163.MCT-11-0762","article-title":"TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens","volume":"11","author":"Hikichi","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.ctrv.2014.11.003_b0445","first-page":"3211","article-title":"RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition. Clinical cancer research: an official journal of the American Association for","volume":"20","author":"van der Meer","year":"2014","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0450","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"11\u201312","key":"10.1016\/j.ctrv.2014.11.003_b0455","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/1947601913478972","article-title":"CDK4: a key player in the cell cycle, development, and cancer","volume":"3","author":"Baker","year":"2012","journal-title":"Genes & Cancer"},{"issue":"18","key":"10.1016\/j.ctrv.2014.11.003_b0460","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-08-3185","article-title":"Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas","volume":"15","author":"Italiano","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ctrv.2014.11.003_b0465","first-page":"5235","article-title":"Expression of cyclin d1 and its association with disease characteristics in bladder cancer","volume":"33","author":"Kopparapu","year":"2013","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0470","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<780::AID-CNCR15>3.0.CO;2-W","article-title":"Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features","volume":"79","author":"Lee","year":"1997","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2014.11.003_b0475","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ajpath.2012.10.017","article-title":"Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer","volume":"182","author":"Fristrup","year":"2013","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.11.003_b0480","first-page":"235","article-title":"Detecting homozygous deletions in the CDKN2A(p16(INK4a))\/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR","volume":"9","author":"Berggren","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.ctrv.2014.11.003_b0485","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1158\/1078-0432.CCR-05-0411","article-title":"Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype","volume":"11","author":"Chapman","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0490","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/path.4017","article-title":"CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma","volume":"227","author":"Rebouissou","year":"2012","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2014.11.003_b0495","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2014.11.003_b0500","doi-asserted-by":"crossref","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4\/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+\/HER2\u2212 advanced breast cancer (PALOMA-1; TRIO-18). In: Proceedings of the 105th annual meeting of the American Association for Cancer Research; 2014 Apr 5\u20139; San Diego Philadelphia (PA): AACR; 2014 [Abstract nr CT101 2014].","DOI":"10.1158\/1538-7445.AM2014-CT101"},{"issue":"6","key":"10.1016\/j.ctrv.2014.11.003_b0505","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s002400050075","article-title":"Different concentrations of two small stress proteins, alphaB crystallin and HSP27 in human urological tumor tissues","volume":"26","author":"Takashi","year":"1998","journal-title":"Urol Res"},{"issue":"3","key":"10.1016\/j.ctrv.2014.11.003_b0510","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0090-4295(02)02289-6","article-title":"Clinical significance of heat shock protein-70 expression in bladder cancer","volume":"61","author":"Syrigos","year":"2003","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ctrv.2014.11.003_b0515","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1464-410X.2008.07669.x","article-title":"Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer","volume":"102","author":"Hadaschik","year":"2008","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ctrv.2014.11.003_b0520","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/1535-7163.MCT-06-0417","article-title":"Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells","volume":"6","author":"Kamada","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.ctrv.2014.11.003_b0525","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1158\/1535-7163.MCT-09-0148","article-title":"Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer","volume":"8","author":"Matsui","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"5s","key":"10.1016\/j.ctrv.2014.11.003_b0530","article-title":"A phase I trial of intravesical antisense oligonucleotide targeting heat shock protein 27 (OGX-427) for the treatment of non-muscle-invasive bladder cancer","volume":"30","author":"So","year":"2012","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2014.11.003_b0535","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.4161\/cc.10.24.18616","article-title":"Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy","volume":"10","author":"Yoshida","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ctrv.2014.11.003_b0540","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/1471-2407-10-481","article-title":"17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells","volume":"10","author":"Karkoulis","year":"2010","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0545","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ijc.26475","article-title":"Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells","volume":"131","author":"Tatokoro","year":"2012","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2014.11.003_b0550","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/1541-7786.MCR-14-0004","article-title":"FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism","volume":"12","author":"Acquaviva","year":"2014","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2014.11.003_b0555","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1464-410X.1982.tb13503.x","article-title":"Immunological profile of patients with transitional cell carcinoma of the bladder","volume":"54","author":"Mukamel","year":"1982","journal-title":"Br J Urol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.11.003_b0560","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.juro.2006.08.078","article-title":"Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines","volume":"177","author":"Loskog","year":"2007","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.ctrv.2014.11.003_b0565","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1073\/pnas.0611618104","article-title":"CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma","volume":"104","author":"Sharma","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"10.1016\/j.ctrv.2014.11.003_b0570","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","article-title":"T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival","volume":"14","author":"Boorjian","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5s","key":"10.1016\/j.ctrv.2014.11.003_b0575","article-title":"Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC)","volume":"32","author":"Powles","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2014.11.003_b0580","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7\u2013H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2014.11.003_b0585","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrclinonc.2013.208","article-title":"Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer","volume":"11","author":"Drake","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2014.11.003_b0590","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0560.2010.01506.x","article-title":"The biologic importance of tumor-infiltrating lymphocytes","volume":"37","author":"Hodi","year":"2010","journal-title":"J Cutan Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2014.11.003_b0595","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","article-title":"Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial","volume":"16","author":"Carthon","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2014.11.003_b0600","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.ctrv.2014.11.003_b0605","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","article-title":"Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.ctrv.2014.11.003_b0610","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","article-title":"Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors","volume":"20","author":"Wainwright","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2014.11.003_b0615","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00262-003-0450-3","article-title":"A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity","volume":"53","author":"Card","year":"2004","journal-title":"Cancer Immunol Immunother"},{"issue":"24","key":"10.1016\/j.ctrv.2014.11.003_b0620","doi-asserted-by":"crossref","first-page":"7765","DOI":"10.1158\/1078-0432.CCR-11-1817","article-title":"Phase I trial of ALT-801, an interleukin-2\/T-cell receptor fusion protein targeting p53 (aa264-272)\/HLA-A\u22170201 complex, in patients with advanced malignancies","volume":"17","author":"Fishman","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6s","key":"10.1016\/j.ctrv.2014.11.003_b0625","article-title":"Phase I\/II clinical trial of ALT-801 a T-cell receptor\/IL-2 fusion protein plus gemcitabine and cisplatin in urothelial cancer","volume":"31","author":"Fishman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2014.11.003_b0630","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1158\/1078-0432.CCR-10-0385","article-title":"AdCD40L immunogene therapy for bladder carcinoma \u2013 the first phase I\/IIa trial","volume":"16","author":"Malmstrom","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T04:41:24Z","timestamp":1598503284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737214001893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":126,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0305737214001893"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.11.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapeutic targets in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}